Obesity is characterized by an accumulation of white adipose tissue (WAT) and a loss of beige adipose tissue (BAT), the latter one being the "good" adipose tissue that burns fat and consumes sugars. Restoring BAT mass in obese patients could counteract obesity-driven metabolic disorders.
ExAdEx-Innov has developed a breakthrough process to unlock the barrier of the ex vivo culture of viable and functional human adipose tissue. This technology allows the ex vivo conversion of WAT into a functional and vascularized BAT biotherapy called ObAdEx. The process for ObAdEx production is tailored for clinical applications and upscaling to industrial production. Transplantation of ObAdEx biotherapy revealed that the product is viable, revascularized and displayed a BAT signature 3 weeks after grafting. Preclinical studies on disease relevant in vivo models are ongoing.
This technology is protected by 2 international patent families and a unique know-how derived from more than 30 years of experience in stem cells and adipose tissue. ObAdEx project got "DeepTech" label by BpiFrance.